Clinical Trials

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma


Study ID
Amgen 20150161

NCT Number
NCT02675452 (Click on the NCT number for more information about the trial)

Research Study Number
00006355

Principle Investigator
Dr. David Siegel

Phase
I

Sponsor
Amgen


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now